摘要
目的:探讨卵巢上皮性癌(简称卵巢癌)P53和c-erbB-2表达的临床意义。方法:用免疫组织《已学法检测P53和C-CrbB-2,结合临床病理及肿瘤的生物学行为进行分析。结果:P53在高分化卵巢癌中的表达频率显著低于中、低分化癌,P53表达阳性组的卵巢癌对化疗不敏感,其预后亦明显劣于阴性组卵巢癌。卵巢癌的c-erbB-2表达与临床期别、组织学类型和分级、残余瘤大小、化疗疗效和预后均无显著相关性。结论:P53是评价卵巢癌化疗耐药性和预后的可靠指标。
Objcctive: To cxplore the clinical significance of P53 and c-erbB-2 expression in ovarian epithelial carcinoma. Metheds: The exprcssion of P53 and c-erbR2 were examined by immunohistochemical method, and the relationship between the expression of two factors and clinicopathologic features, resistance to chcmothcrapy and prognosis were analyzed. Results: The exprcssion P53 had significant lower frequeney in well-differentiated ovarian tumor than mid- and poor-differentiated ovarian tumor. P53 positive tumors related with drug resistance and poor prognosis significantly. The expression of c-crbB-2 was not associated with FlGD stage, histologic type, grade and residual tumor. c-erbB-2 did not appear to be a valuable drug rcsistant factor. Conclusion :P53 expression in ovari-an cancer is related to drug resistance, and it is a useful prognostic factor.
出处
《河北医药》
CAS
1999年第5期344-347,共4页
Hebei Medical Journal